Für das "Produkt" WP1066 wird eine Markteinführung in 2027 erwartet, jedoch "kauft" sich MBI die Lizenz nur für Deutschland in diesem Quartal zurück.
https://ir.moleculin.com/all-sec-filings/content/...617-19-000169.pdf
Das Auslizenzierungsabkommen wurde im Februar 2019 zwischen beiden Vertragspartner abgeschlossen,
News: https://ir.moleculin.com/press-releases/detail/...deal-to-accelerate,
Welche Absicht steht nun dahinter, haben Sie einen Partner in Deutschland an Bord?
@Stille Mitleser, was ist los mit Euch, habt Ihr keine Phantasie?
". On July 30, 2019, the Company and Exploration entered into a License Modification Agreement pursuant to which the Company agreed to issue
Exploration shares of Company common stock valued at $0.5 million (based on the greater of the closing price of the common stock on the date of the agreement or the 10-day
average closing price prior to the date of the agreement) in exchange for the modifying the license agreements to: (i) limit the licensed territory solely to Poland; and (ii) limit
the patent rights and technology rights licensed to Exploration to the patent rights and technology rights that existed on the date the original license agreements were entered into
with Dermin. On August 8, 2019, the Company issued 429,978 shares of Company common stock to Exploration to satisfy this commitment...
...On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio to WPD Pharmaceuticals sp. z o.o. (“WPD”) (the “WPD Agreement”). WPD is affiliated with Dr. Waldemar Priebe, one of the Company's founders and largest shareholder. Under
the WPD Agreement, the Company granted WPD a royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell
products in the field of human therapeutics under the licensed intellectual property in the countries of Germany, Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova,
Romania, Armenia, Azerbaijan, Georgia, Slovakia, Czech Republic, Hungary, Uzbekistan, Kazakhstan, Greece, Austria, Russia, Netherlands, Turkey, Belgium, Switzerland,
Sweden, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland (“licensed territories”), provided that the Company has the right to buyback Germany from the
licensed territories by making a payment $0.5 million. On July 30, 2019, the Company entered into the aforementioned July 30, 2019 agreement with Dermin that satisfied the
foregoing buyback right, and as such, Germany is no longer considered part of the licensed territories..."
|
Thread abonnieren
